Jpmorgan Chase & CO Passage Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Passage Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 273 shares of PASG stock, worth $139. This represents 0.0% of its overall portfolio holdings.
Number of Shares
273
Previous 273
-0.0%
Holding current value
$139
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PASG
# of Institutions
47Shares Held
38.7MCall Options Held
7.7KPut Options Held
0-
Orbimed Advisors LLC San Diego, CA9.82MShares$5.01 Million0.16% of portfolio
-
Lynx1 Capital Management LP San Juan, PR8.43MShares$4.3 Million2.11% of portfolio
-
Vestal Point Capital, LP New York, NY6.1MShares$3.11 Million0.32% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$1.27 Million1.8% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.46MShares$1.25 Million0.02% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $27.8M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...